Czerwińska Ewa, Nittner-Marszalska Marita, Pawłowicz Robert, Szenborn Leszek
Department of Paediatrics and Infectious Diseases, Wroclaw Medical University, ul. Tytusa Chałubińskiego 2-2a, 50-368 Wroclaw, Poland.
Department of Internal Medicine, Pneumology and Allergology, Wroclaw Medical University, ul. Marii Skłodowskiej-Curie 66, 50-369 Wroclaw, Poland.
Vaccines (Basel). 2021 Apr 2;9(4):344. doi: 10.3390/vaccines9040344.
Allergen immunotherapy (AIT) is a standard treatment for venom allergy. Our purpose was to determine if the administration of both allergen and protective vaccines during one visit is safe and if such a procedure does not deteriorate the tolerance of both vaccines. As current guidelines are based on theoretical assumptions, our aim was to establish the safety and tolerance of shortening the recommended interval between vaccinations. During two influenza seasons, 44 adult patients, with a history of systemic allergic reactions after a Hymenoptera sting, underwent 58 simultaneous allergen and seasonal influenza vaccinations (study group) while in the maintenance phase of venom immunotherapy (VIT). The control group consisted of 57 healthy adults who were vaccinated against influenza only. The conditions of the patients were monitored during hospital visits, and via telecommunication methods to evaluate the safety and tolerance of the procedure. Within the study group, there were no immediate or delayed allergic reactions after vaccinations. The presence of common, adverse influenza vaccine reactions among study group patients (29%) and control group patients (32%) did not differ significantly ( = 0.841). We did not observe a difference in the frequency of various adverse reactions in either group or a dependence of previous vaccinations against influenza on the occurrence of adverse reactions. The most frequent occurrences were local adverse reactions. All adverse reactions were resolved without treatment. These findings demonstrate the safety and tolerance of an influenza vaccination and Hymenoptera venom immunotherapy administration during one visit.
变应原免疫疗法(AIT)是治疗毒液过敏的标准方法。我们的目的是确定在一次就诊时同时给予变应原和预防性疫苗是否安全,以及这样的操作是否不会降低两种疫苗的耐受性。由于当前指南基于理论假设,我们的目标是确定缩短推荐的疫苗接种间隔时间的安全性和耐受性。在两个流感季节期间,44名有膜翅目昆虫叮咬后发生全身过敏反应病史的成年患者,在毒液免疫疗法(VIT)的维持阶段同时接受了58次变应原和季节性流感疫苗接种(研究组)。对照组由57名仅接种流感疫苗的健康成年人组成。在患者就诊期间以及通过远程通讯方法对患者情况进行监测,以评估该操作的安全性和耐受性。在研究组中,接种疫苗后未出现即刻或延迟过敏反应。研究组患者(29%)和对照组患者(32%)中常见的流感疫苗不良反应发生率无显著差异( = 0.841)。我们未观察到两组中各种不良反应的频率有差异,也未观察到既往流感疫苗接种情况与不良反应发生之间存在相关性。最常见的是局部不良反应。所有不良反应未经治疗即自行缓解。这些发现证明了在一次就诊时进行流感疫苗接种和膜翅目昆虫毒液免疫疗法的安全性和耐受性。